Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Recommendation of “Moderate Buy” by Brokerages

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) has earned an average rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $22.25.

PHAT has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, January 22nd. Raymond James Financial assumed coverage on Phathom Pharmaceuticals in a research note on Thursday, December 11th. They set a “strong-buy” rating and a $28.00 target price for the company. Stifel Nicolaus set a $28.00 price target on Phathom Pharmaceuticals in a research note on Thursday, February 26th. Barclays started coverage on Phathom Pharmaceuticals in a research note on Monday, December 8th. They issued an “equal weight” rating and a $16.00 price target on the stock. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Phathom Pharmaceuticals in a research report on Wednesday, January 14th.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Phathom Pharmaceuticals in the 4th quarter valued at approximately $27,000. Jones Financial Companies Lllp boosted its position in shares of Phathom Pharmaceuticals by 442.6% during the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock worth $30,000 after purchasing an additional 2,058 shares during the period. Raymond James Financial Inc. acquired a new stake in Phathom Pharmaceuticals in the 2nd quarter valued at approximately $30,000. Kestra Advisory Services LLC acquired a new stake in Phathom Pharmaceuticals in the 4th quarter valued at approximately $38,000. Finally, Ameritas Investment Partners Inc. raised its position in Phathom Pharmaceuticals by 39.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,311 shares of the company’s stock valued at $41,000 after purchasing an additional 1,216 shares during the period. 99.01% of the stock is currently owned by institutional investors and hedge funds.

Phathom Pharmaceuticals Price Performance

Shares of PHAT stock opened at $11.15 on Friday. The company has a market capitalization of $878.62 million, a PE ratio of -3.64 and a beta of 0.51. The firm’s 50-day moving average is $12.59 and its two-hundred day moving average is $13.44. Phathom Pharmaceuticals has a 12 month low of $2.21 and a 12 month high of $18.31.

Phathom Pharmaceuticals (NASDAQ:PHAT) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. The firm had revenue of $57.58 million during the quarter, compared to analysts’ expectations of $57.44 million. Sell-side analysts forecast that Phathom Pharmaceuticals will post -4.78 EPS for the current year.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.